To the Editor: Dr Hare and colleagues1 investigated the efficacy and safety of allogeneic mesenchymal stem cells (MSCs) administered by transendocardial stem cell injection compared with autologous MSCs in patients with chronic left ventricular dysfunction secondary to myocardial infarction. The results are encouraging; however, we have some concerns about the study.
First, because aging impairs the survival and differentiation potential of MSCs, which may limit their therapeutic efficacy,2 what were the screening criteria for donors in the study? Were there any age limits for donors?
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.